Subscribe
Close
  • Free for qualified executives and consultants to industry

  • Receive quarterly issues of Area Development Magazine and special market report and directory issues

Renew

Catalent Expands Operations Complex in Bloomington, Indiana

04/24/2020
Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, completed its $14 million expansion to increase the biologics packaging capabilities and capacity at its facility in Bloomington, Indiana.

The completed expansion adds 15,000 square feet of packaging infrastructure to the biologics and sterile manufacturing site, including five new packaging suites and a new quality control laboratory.

“The completion of this expansion marks a major milestone for our late-stage and commercial customers, allowing Catalent to focus on more complex device assembly and packaging needs for biologic products at higher volumes,” commented Mike Riley, Region President, Biologics North America. “This state-of-the-art equipment adds to our growing network of global packaging capabilities alongside our Brussels, Belgium, and Anagni, Italy drug product manufacturing sites.”

Catalent’s 875,000 square-feet facility in Bloomington has deep expertise in sterile formulation and extensive biomanufacturing and drug product fill/finish capacity across liquid and lyophilized vials, prefilled syringes, and cartridges.

Catalent said it has developed strategic partnerships with industry leaders to bring new technologies and integrated capabilities to customers with three new state-of-the-art packaging lines, including an Optima combination syringe assembly machine, an automated Mikron auto-injector assembly machine, and Dividella’s NeoTOP x (NTX) top-load cartoner with both semi-automated and fully-automated configurations.

According to company officials, All three high-speed lines are fully qualified and ready to provide customers faster and more flexible packaging solutions for vials, syringes, and devices with no glass-to-glass contact.

Share

Exclusive Research